Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE-Asia phase 3 study of AZD6234 in obesity or overweight with weight-related comorbidities, with or without type 2 diabetes
CTR20263687Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing AZD6234 with Placebo (2 arms). Started Sep 2026; status: active.
02
Drugs
lenbelintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263687.